AAPL   366.70 (+0.71%)
MSFT   207.62 (+1.43%)
FB   235.10 (-1.04%)
GOOGL   1,480.65 (+2.68%)
AMZN   2,904.95 (+0.91%)
NVDA   386.44 (+1.37%)
BABA   223.95 (+3.70%)
GE   6.85 (+1.63%)
TSLA   1,205.52 (+7.67%)
AMD   52.35 (-0.44%)
ACB   12.05 (-1.79%)
F   6.08 (+1.67%)
GILD   76.61 (+0.72%)
BAC   23.46 (+0.82%)
AAPL   366.70 (+0.71%)
MSFT   207.62 (+1.43%)
FB   235.10 (-1.04%)
GOOGL   1,480.65 (+2.68%)
AMZN   2,904.95 (+0.91%)
NVDA   386.44 (+1.37%)
BABA   223.95 (+3.70%)
GE   6.85 (+1.63%)
TSLA   1,205.52 (+7.67%)
AMD   52.35 (-0.44%)
ACB   12.05 (-1.79%)
F   6.08 (+1.67%)
GILD   76.61 (+0.72%)
BAC   23.46 (+0.82%)
AAPL   366.70 (+0.71%)
MSFT   207.62 (+1.43%)
FB   235.10 (-1.04%)
GOOGL   1,480.65 (+2.68%)
AMZN   2,904.95 (+0.91%)
NVDA   386.44 (+1.37%)
BABA   223.95 (+3.70%)
GE   6.85 (+1.63%)
TSLA   1,205.52 (+7.67%)
AMD   52.35 (-0.44%)
ACB   12.05 (-1.79%)
F   6.08 (+1.67%)
GILD   76.61 (+0.72%)
BAC   23.46 (+0.82%)
AAPL   366.70 (+0.71%)
MSFT   207.62 (+1.43%)
FB   235.10 (-1.04%)
GOOGL   1,480.65 (+2.68%)
AMZN   2,904.95 (+0.91%)
NVDA   386.44 (+1.37%)
BABA   223.95 (+3.70%)
GE   6.85 (+1.63%)
TSLA   1,205.52 (+7.67%)
AMD   52.35 (-0.44%)
ACB   12.05 (-1.79%)
F   6.08 (+1.67%)
GILD   76.61 (+0.72%)
BAC   23.46 (+0.82%)
Log in

NASDAQ:ADROAduro BioTech Stock Price, Forecast & News

$2.49
-0.01 (-0.40 %)
(As of 07/2/2020 02:22 PM ET)
Add
Compare
Today's Range
$2.41
Now: $2.49
$2.54
50-Day Range
$2.14
MA: $2.64
$3.37
52-Week Range
$0.90
Now: $2.49
$4.04
Volume185,394 shs
Average Volume812,152 shs
Market Capitalization$201.29 million
P/E RatioN/A
Dividend YieldN/A
Beta0.31
Aduro BioTech, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy and multiple myeloma; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and NK cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Read More
Aduro BioTech logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADRO
CUSIPN/A
Phone510-848-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.26 million
Book Value$0.81 per share

Profitability

Net Income$-82,370,000.00
Net Margins-243.93%

Miscellaneous

Employees152
Market Cap$201.29 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive ADRO News and Ratings via Email

Sign-up to receive the latest news and ratings for ADRO and its competitors with MarketBeat's FREE daily newsletter.

Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions

How has Aduro BioTech's stock been impacted by COVID-19 (Coronavirus)?

Aduro BioTech's stock was trading at $2.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ADRO stock has increased by 5.5% and is now trading at $2.49. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aduro BioTech?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Aduro BioTech.

When is Aduro BioTech's next earnings date?

Aduro BioTech is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Aduro BioTech.

How were Aduro BioTech's earnings last quarter?

Aduro BioTech Inc (NASDAQ:ADRO) released its earnings results on Monday, May, 4th. The biotechnology company reported ($0.09) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.05. The biotechnology company earned $13.95 million during the quarter, compared to the consensus estimate of $8.81 million. Aduro BioTech had a negative net margin of 243.93% and a negative return on equity of 86.31%. View Aduro BioTech's earnings history.

What price target have analysts set for ADRO?

5 brokerages have issued 1-year price targets for Aduro BioTech's shares. Their forecasts range from $4.00 to $7.00. On average, they expect Aduro BioTech's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 120.9% from the stock's current price. View analysts' price targets for Aduro BioTech.

Has Aduro BioTech been receiving favorable news coverage?

News articles about ADRO stock have been trending very negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aduro BioTech earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Aduro BioTech.

Are investors shorting Aduro BioTech?

Aduro BioTech saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 2,920,000 shares, an increase of 6.6% from the May 31st total of 2,740,000 shares. Based on an average daily trading volume, of 639,700 shares, the days-to-cover ratio is currently 4.6 days. Currently, 6.3% of the shares of the stock are sold short. View Aduro BioTech's Current Options Chain.

Who are some of Aduro BioTech's key competitors?

What other stocks do shareholders of Aduro BioTech own?

Who are Aduro BioTech's key executives?

Aduro BioTech's management team includes the following people:
  • Mr. Stephen T. Isaacs, Chairman, CEO & Pres (Age 70)
  • Dr. Andrea van Elsas, Chief Scientific Officer (Age 52)
  • Mr. Blaine E. Templeman, Chief Admin. Officer & Chief Legal Officer (Age 53)
  • Ms. Jennifer Lew, Chief Financial Officer (Age 46)
  • Ms. Alexandra Santos, Exec. Director of Corp. Affairs & Investor Relations

When did Aduro BioTech IPO?

(ADRO) raised $119 million in an IPO on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aduro BioTech's stock symbol?

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

How do I buy shares of Aduro BioTech?

Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aduro BioTech's stock price today?

One share of ADRO stock can currently be purchased for approximately $2.49.

How big of a company is Aduro BioTech?

Aduro BioTech has a market capitalization of $201.29 million and generates $17.26 million in revenue each year. The biotechnology company earns $-82,370,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Aduro BioTech employs 152 workers across the globe.

What is Aduro BioTech's official website?

The official website for Aduro BioTech is www.aduro.com.

How can I contact Aduro BioTech?

Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.